Osteonecrosis of the jaw associated with pembrolizumab.
Journal
Oral surgery, oral medicine, oral pathology and oral radiology
ISSN: 2212-4411
Titre abrégé: Oral Surg Oral Med Oral Pathol Oral Radiol
Pays: United States
ID NLM: 101576782
Informations de publication
Date de publication:
Jul 2023
Jul 2023
Historique:
received:
18
10
2022
revised:
20
12
2022
accepted:
28
12
2022
pmc-release:
01
07
2024
medline:
19
6
2023
pubmed:
22
2
2023
entrez:
21
2
2023
Statut:
ppublish
Résumé
We report a case of osteonecrosis of the jaw (ONJ) with pembrolizumab, a rare yet possibly emerging complication. In this case, a temporal relationship between the development of ONJ and the patient's treatment regimen suggested an association between pembrolizumab/GVD therapy and the development of ONJ. Thrombocytosis and anatomic factors may also have played a role. The number of patients using pembrolizumab will likely continue to increase. We document this instance in order to better inform dental treatment around cancer patients undergoing pembrolizumab therapy.
Identifiants
pubmed: 36804060
pii: S2212-4403(22)01310-4
doi: 10.1016/j.oooo.2022.12.013
pmc: PMC10395506
mid: NIHMS1875716
pii:
doi:
Substances chimiques
Diphosphonates
0
Bone Density Conservation Agents
0
pembrolizumab
DPT0O3T46P
Types de publication
Case Reports
Langues
eng
Sous-ensembles de citation
IM
Pagination
e11-e14Subventions
Organisme : NCI NIH HHS
ID : P30 CA008748
Pays : United States
Informations de copyright
Copyright © 2023 Elsevier Inc. All rights reserved.
Références
J Oral Maxillofac Surg. 2014 Oct;72(10):1938-56
pubmed: 25234529
Support Care Cancer. 2017 Oct;25(10):3017-3030
pubmed: 28707167
J Stomatol Oral Maxillofac Surg. 2020 Dec;121(6):740-742
pubmed: 32413422
Front Immunol. 2018 Nov 27;9:2737
pubmed: 30542345
Int J Mol Sci. 2022 Jan 07;23(2):
pubmed: 35054824
Oral Oncol. 2015 Dec;51(12):e100-1
pubmed: 26421864